Alcon Inc (ALC) stock
Close on Nov 12, 2026Market cap $35.01BP/E 36.3Yield –
Alcon Inc grew revenue 4.9% to $10.40B over fiscal 2025. Operating income fell 3.8% to $1.36B, moving the operating margin from 14.3% to 13.1%. Free cash flow was $1.73B, up 7.7% from a year earlier. At the latest close the market valued the company at $35.01B, 36.3 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $35.01B
- P/E ratio
- 36.3
- Price to sales
- 3.37
- Price to book
- 1.62
- Dividend yield
- –
- Free cash flow yield
- 4.94%
Fundamentals
- Revenue
- $10.40B
- Net income
- $980.00M
- EPS, diluted
- $1.98
- Free cash flow
- $1.73B
- Book value per share
- $44.19
- Diluted shares
- 489M
Trading
- Previous close
- $72.46
- Open
- $73.06
- Day's range
- $71.64 – $73.95
- Volume
- 2,252,078
- Average volume (20 days)
- 2,249,165
- Beta (5 years)
- 0.81
- 52-week range
- $61.84 – $87.64
- RSI (14 days)
- 53.4
- Volatility (1 year)
- 28.9%
- Relative volume
- 1.16×
- WACC
- 8.4%
Market cap history
Month-end market cap since 2009, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ALC | S&P 500 | Difference | ALC per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +11.6% | -2.7% | +14.3 pts | ||
| 3 months | -2.4% | -1.7% | −0.6 pts | ||
| Year to date | -8.4% | +11.9% | −20.3 pts | ||
| 1 year | -9.1% | +12.0% | −21.1 pts | ||
| 3 years | -0.3% | +78.2% | −78.5 pts | -0.1% | +21.2% |
| 5 years | -9.9% | +73.2% | −83.2 pts | -2.1% | +11.6% |
| 10 years | +510.2% | +309.6% | +200.5 pts | +19.8% | +15.1% |
Fifteen years at a glance
Fiscal years 2006 to 2025, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Alcon filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Alcon
Ophthalmic Goods
Alcon develops, manufactures, and distributes eye care products through two primary divisions: Surgical and Vision Care. Its Surgical segment offers implantable intraocular lenses, surgical equipment, consumables, and diagnostic platforms for procedures treating conditions such as cataracts, glaucoma, vitreoretinal disorders, and refractive errors. The Vision Care segment supplies daily disposable, reusable, and color contact lenses, alongside ocular health remedies including dry eye solutions, allergy treatments, glaucoma therapies, and lens care items. The company serves eye care professionals, ophthalmic surgeons, clinics, and direct consumers worldwide.
Company profile, executives and historyAlcon stock: common questions
What is Alcon's stock price?
ALC closed at $71.83 on Nov 12, 2026, down 0.87% on the day. Over the past 52 weeks it traded between $61.84 and $87.64.
What is Alcon's market cap?
Alcon was worth $35.01B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is ALC's P/E ratio?
ALC trades at 36.3 times earnings, based on diluted earnings per share of $1.98 over fiscal 2025.
How much revenue does Alcon make?
Alcon reported revenue of $10.40B for fiscal 2025, up 4.9% from a year earlier.
Does Alcon pay a dividend?
No. Alcon has not paid a cash dividend over the last twelve months.
How has ALC stock performed over the past year?
Including dividends, ALC returned -9.1% over the past year, against +12.0% for the S&P 500.
How many ALC shares are sold short?
18M shares were sold short at the latest FINRA report, 3.78% of the float, or 12.6 days of average trading volume.
Who are Alcon's competitors?
Companies most similar to Alcon by business, industry and size include BLCO, COO, STAA, BAX, EYE.
See a number that looks wrong?